Influenza B NA Inhibitors

Influenza B NA inhibitors target the neuraminidase (NA) protein of the influenza B virus, playing an essential role in curbing viral dissemination. Direct inhibitors like Oseltamivir, Zanamivir, and Peramivir competitively or allosterically inhibit the sialidase activity of the NA protein, effectively blocking the enzyme's active site and the cleavage of terminal sialic acids from host cell glycoconjugates. This action leads to an obstruction in the release of viral progeny from infected cells. 2-Deoxy-D-glucose takes a more indirect route by hampering N-linked glycosylation of NA through the inhibition of glycolysis. Baicalein acts in a similar direct manner, targeting the active site to inhibit enzymatic activity.

Other inhibitors operate through distinct but still effective pathways. For example, Chloroquine alters endosomal pH, affecting a crucial step in the viral life cycle, whereas Amantadine targets the M2 ion channel to similarly affect pH-dependent processes that facilitate NA function. Indinavir, generally an HIV protease inhibitor, interferes with the endocytosis pathway and thus affects NA localization. Genistein inhibits tyrosine kinases, disrupting cellular signaling pathways that would typically facilitate NA transport to the host cell membrane. In a different approach, Dextran Sulfate binds to the influenza virus surface, blocking the NA-sialic acid interaction. Finally, Ribavirin disrupts nucleic acid synthesis, thereby affecting NA expression levels. Each of these compounds employs a unique approach to disturb the multifaceted mechanisms through which NA operates.